RT Journal Article
T1 The current status of mesenchymal stromal cells: controversies, unresolved issues and some promising solutions to improve their therapeutic efficacy
A1 García Bernal, David
A1 García Arranz, Mariano
A1 Yáñez, Rosa
A1 Hervás Salcedo, Rosario
A1 Cortés Rubio, José Alfonso
A1 Fernández García, María
A1 Hernando Rodríguez, Miriam
A1 Quintana Bustamante, Óscar
A1 Bueren, Juan A.
A1 García Olmo, Damián
A1 Moraleda, Jose María
A1 Segovia, Jose Carlos
A1 Zapata González, Agustín
AB Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Although the therapeutic efficacy of these cells has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. On the other hand, diverse controversial issues on the biology and clinical applications of MSCs, including their specific phenotype, the requirement of an inflammatory environment to induce immunosuppression, the relevance of the cell dose and their administration schedule, the cell delivery route (intravascular/systemic vs. local cell delivery), and the selected cell product (i.e., use of autologous vs. allogeneic MSCs, freshly cultured vs. frozen and thawed MSCs, MSCs vs. MSC-derived extracellular vesicles, etc.) persist. In the current review article, we have addressed these issues with special emphasis in the new approaches to improve the properties and functional capabilities of MSCs after distinct cell bioengineering strategies.
PB Frontiers Media
YR 2021
FD 2021-03-16
LK https://hdl.handle.net/20.500.14352/8502
UL https://hdl.handle.net/20.500.14352/8502
LA eng
NO García-Bernal D, García-Arranz M, Yáñez RM, Hervás-Salcedo R, Cortés A, Fernández-García M, et al. The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy. Front Cell Dev Biol 2021;9:650664. https://doi.org/10.3389/fcell.2021.650664.
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Instituto de Salud Carlos III (ISCIII)/Fondo Europeo de Desarrollo Regional
NO Comunidad de Madrid
DS Docta Complutense
RD 18 abr 2025